Among the stocks showing the most potent sustained momentum right now on the OTC, Vivos Inc (OTCMKTS:RDGL) has to be very high on the list. Shares have powering over 800% higher in the past 10 days, with trading volume exploding following a company deal with convertible debt holders to halt conversions and toxic selling.
To help drive the story, the company just announced that the Vista Veterinary Hospital in Kennewick WA, located near Vivos’ headquarters, has been selected for the commercial launch of IsoPet therapy. According to the release, “After several meetings with the clinic’s veterinarian owners, a Memorandum of Understanding has been signed.”
Vivos Inc (OTCMKTS:RDGL) has developed an Yttrium-90 based brachytherapy injectable device, for the treatment of tumors in animals (IsoPet) and in humans (Radiogel). Brachytherapy uses highly localized radiation to destroy cancerous tumors by placing a radioactive isotope directly inside the treatment area using the company’s proprietary hydrogel formulation.
The injection delivers therapeutic radiation from within the tumor without the entrance skin dose and associated side effects of treatment that characterize external-beam radiation therapy. This feature allows safe delivery of higher doses needed for treating both non-resectable and radiation-resistant cancers.
IsoPet for treating animals uses the same technology as RadioGelTM for treating humans. The Food and Drug Administration advised using different product names in order to avoid confusion and cross-use.
IsoPet is a hydrogel liquid containing tiny yttrium-90 phosphate particles that may be administered directly into a tumor. This hydrogel is an yttrium-90 carrier at room temperature that gels within the tumor interstitial space after injection to keep the radiation source safely in place. The short-range beta radiation from yttrium-90 localizes the dose within the treatment area so that normal organs and tissues are not adversely affected.
IsoPet also has a short half-life – delivering more than 90% of its therapeutic radiation within 10 days. This compares favorably to other available treatment options requiring up to six weeks or more to deliver a full course of radiation therapy. Therapy can be safely administered as an out-patient procedure and the patient may return home without subsequent concern for radiation dose to the family.
The IsoPet Solutions division is using university veterinary hospitals to demonstrate the safety and therapeutic effectiveness for different animal cancers. The testing on feline sarcoma at the Washington State University is completed and the testing on canine soft tissue sarcomas at University of Missouri will begin in the near future.
The Company recently obtained confirmation from the FDA Center for Veterinary Medicine that IsoPet is classified as a device for skin cancer therapy in cats and dogs. The FDA also reviewed and approved the product labeling. FDA does not require pre-market approval for veterinary devices so no additional approval is required for treating skin cancer, which is the largest market sector. Following this demonstration phase, Vivos can begin to generate revenues through the sale of IsoPet to University animal hospitals and private veterinary clinic consortiums.
The Company is also engaging the FDA for clearance to market RadioGel for the treatment of advanced basal and squamous cell skin cancers in humans.
Find out when $RDGL stock reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.
We’ve witnessed more than 710% during the past month in terms of shareholder gains in the listing. Moreover, the stock has seen interest climb, with an increase in recent trading volume of topping 400% over what the stock has registered over the longer term.
Dr. Mike Korenko, Vivos CEO stated “Best management practice dictates that we pilot partnering with a private clinic prior to expanding to other regional clinics across the county. We will gain practical experience, such as the effectiveness of our certification training and the time and effort required to obtain the Radioactive Material License. This will optimize the process of engaging with other treatment centers”.
At this time, carrying a capital value in the market of $10.62M, RDGL has virtually no cash on the books, which compares with about $10.7M in total current liabilities. One should also note that debt has been growing over recent quarters. RDGL is pre-revenue at this stage. You can bet we will update this one again as new information comes into view. Sign-up for continuing coverage on shares of $RDGL stock, as well as other hot stock picks, get our free newsletter today and get our next breakout pick!
Disclosure: we hold no position in $RDGL, either long or short, and we have not been compensated for this article.